Genmab CEO on royalties defeat: "I'm sad and disappointed"
In April, Genmab suffered a defeat in an arbitration case concerning drug Darzalex. Though he had hoped for a different outcome, CEO Jan van de Winkel says it was a ”complex” decision not to contest the ruling, and that a conclusion was sorely needed.
by andreas lønstrup, translated by daniel pedersen
A yearlong royalties strife between Genmab and its partner Janssen was finally over in April, when three arbitrators ruled in favor of the latter firm.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab throws in the towel – won't contest royalties ruling
For subscribers
Genmab loses royalties case against Janssen
For subscribers
